Synopsis
Synopsis
0
CEP/COS
0
EU WC
0
VMF
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. B 1793
2. B 1939
3. B-1793
4. B-1939
5. E 7389
6. E-7389
7. Er 086526
8. Er-086526
9. Er-86526
10. Er086526
11. Eribulin
12. Eribulin (as Mesylate)
13. Eribulin Mesilate
14. Eribulin Monomethanesulfonate
15. Halaven
16. Nsc 707389
17. Nsc-707389
18. Nsc707389
1. Halaven
2. Eribulin Mesilate
3. 441045-17-6
4. Eribulin (mesylate)
5. Eribulin Mesylate [usan]
6. Eribulin (as Mesylate)
7. E7389
8. Eribulin Monomethanesulfonate
9. Av9u0660cw
10. Chebi:70710
11. E 7389
12. E-7389
13. Eribulin Mesilate (jan)
14. Eribulin Mesylate (usan)
15. B-1939
16. (1s,3s,6s,9s,12s,14r,16r,18s,20r,21r,22s,26r,29s,31r,32s,33r,35r,36s)-20-[(2s)-3-amino-2-hydroxypropyl]-21-methoxy-14-methyl-8,15-dimethylidene-2,19,30,34,37,39,40,41-octaoxanonacyclo[24.9.2.13,32.13,33.16,9.112,16.018,22.029,36.031,35]hentetracontan-24-one;methanesulfonic Acid
17. Eribulin Mesilate [jan]
18. Nsc-707389
19. Er-086526
20. Unii-av9u0660cw
21. Halaven (tn)
22. B1939 Mesylate
23. E7389 Mesylate
24. Er-086526 Mesylate
25. Chembl1683544
26. Eribulin Mesylate [vandf]
27. Eribulin Mesilate [mart.]
28. Eribulin Mesilate [who-dd]
29. Ex-a4873
30. Eribulin Mesylate [ema Epar]
31. Hy-13442a
32. Eribulin Mesylate [orange Book]
33. Eribulin Monomethanesulfonate [mi]
34. D08914
35. Q27882076
36. B1939 Mesylate; E7389 Mesylate; Er-086526 Mesylate
37. (2r,3r,3as,7r,8as,9s,10ar,11s,12r,13ar,13bs,15s,18s,21s,24s,26r,28r,29as)-2-((2s)-3-amino-2-hydroxypropyl)-3-methoxy-26-methyl-20,27-dimethylidenehexacosahydro-11,15:18,21:24,28-triepoxy-7,9-ethano-12,15-methano-9h,15h-furo(3,2-i)furo(2',3':5,6)pyrano(4,3-b)(1,4)dioxacyclopentacosin-5(4h)-one Methanesulfonate (salt)
38. 11,15:18,21:24,28-triepoxy-7,9-ethano-12,15-methano-9h,15h-furo(3,2-i)furo(2',3':5,6)pyrano(4,3-b)(1,4)dioxacyclopentacosin-5(4h)-one, 2-((2s)-3- Amino-2-hydroxypropyl)hexacosahydro-3-methoxy-26-methyl-20,27-bis(methylene)-, 2r,3r,3as,7r,8as,9s,10ar,11s,12r,13ar,13bs,15s,18s,21s,24s,26r,28r,29as)-, Methanesulfonate (salt)
39. 2-(3-amino-2-hydroxypropyl)hexacosahydro-3-methoxy-26-methyl-20,27-bis(methylene)11,15-18,21-24,28-triepoxy-7,9-ethano-12,15-methano-9h,15h-furo(3,2-i)furo(2',3'-5,6)pyrano(4,3-b)(1,4)dioxacyclopentacosin-5-(4h)-one Methanesulfonate
Molecular Weight | 826.0 g/mol |
---|---|
Molecular Formula | C41H63NO14S |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 15 |
Rotatable Bond Count | 4 |
Exact Mass | 825.39692686 g/mol |
Monoisotopic Mass | 825.39692686 g/mol |
Topological Polar Surface Area | 209 Ų |
Heavy Atom Count | 57 |
Formal Charge | 0 |
Complexity | 1470 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 19 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 2 | |
---|---|
Drug Name | Halaven |
PubMed Health | Eribulin (Injection) |
Drug Classes | Antineoplastic Agent |
Drug Label | HALAVEN (eribulin mesylate) Injection is a non-taxane microtubule dynamics inhibitor. Eribulin mesylate is a synthetic analogue of halichondrin B, a product isolated from the marine sponge Halichondria okadai. The chemical name for eribulin mesyl... |
Active Ingredient | Eribulin mesylate |
Dosage Form | Solution |
Route | Intravenous |
Strength | 1mg/2ml (0.5mg/ml) |
Market Status | Prescription |
Company | Eisai |
2 of 2 | |
---|---|
Drug Name | Halaven |
PubMed Health | Eribulin (Injection) |
Drug Classes | Antineoplastic Agent |
Drug Label | HALAVEN (eribulin mesylate) Injection is a non-taxane microtubule dynamics inhibitor. Eribulin mesylate is a synthetic analogue of halichondrin B, a product isolated from the marine sponge Halichondria okadai. The chemical name for eribulin mesyl... |
Active Ingredient | Eribulin mesylate |
Dosage Form | Solution |
Route | Intravenous |
Strength | 1mg/2ml (0.5mg/ml) |
Market Status | Prescription |
Company | Eisai |
Halaven monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have progressed after at least one chemotherapeutic regimens for advanced disease (see section 5. 1). Prior therapy should have included an anthracycline and a taxane unless patients were not suitable for these treatments.
Halaven is indicated for the treatment of adult patients with unresectable liposarcoma who have received prior anthracycline containing therapy (unless unsuitable) for advanced or metastatic disease (see section 5. 1).
L01XX41
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
Patent Expiration Date : 2027-07-08
US Patent Number : RE46965*PED
Drug Substance Claim :
Drug Product Claim :
Application Number : 201532
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2027-07-08
Patent Expiration Date : 2024-01-20
US Patent Number : 6214865*PED
Drug Substance Claim :
Drug Product Claim :
Application Number : 201532
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2024-01-20
Exclusivity Code : M-280
Exclusivity Expiration Date : 2025-09-13
Application Number : 201532
Product Number : 1
Exclusivity Details :
Exclusivity Code : PED
Exclusivity Expiration Date : 2026-03-13
Application Number : 201532
Product Number : 1
Exclusivity Details :
Patent Expiration Date : 2019-06-16
Date Granted : 2008-10-07
Brand Name : HALAVEN
Patent Number : 2335300
Filing Date : 1999-06-16
Strength per Unit : 0.5 mg / mL
Dosage Form : Solution for injection
Human Or VET : Human
Route of Administration : Intravenous
Patent Expiration Date : 2019-06-16
Date Granted : 2008-10-07
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?